Natural killer cell functional genetics and donor-specific antibody-triggered microvascular inflammationMatthias Diebold, Georg A. Böhmig, Konstantin Doberer et al.|American Journal of Transplantation|2023Cited by 26
Natural Killer Cell Presence in Antibody-Mediated RejectionMatthias Diebold, Georg A. Böhmig, Evan A. Farkash et al.|Transplant International|2024Cited by 19
225.3: Randomized phase 2 trial of felzartamab in humoral transplant rejection.Katharina A. Mayer, Georg A. Böhmig, Eva Schrezenmeier et al.|Transplantation|2024Cited by 0